COVID-19-induced transaminitis and hyperbilirubinemia:Presentation and outcomes  

作　　者：Zeinab Nabil Ahmed Said Safinaz Adel El Habashy Samy Zaky ESCMID Study Group for Viral Hepatitis 

机构地区：[1]Department of Medical Microbiology and Immunology,Faculty of Medicine(For Girls),Al-Azhar University,Cairo 11754,Nasr City,Egypt [2]Department of Pediatrics,Ain Shams University,Cairo 11391,Abbaseia,Egypt [3]Department of Hepato-gastroenterology and Infectious Diseases,Faculty of Medicine(For Girls),Al-Azhar University,Cairo 11754,Egypt [4]不详

出　　处：《World Journal of Gastroenterology》2023年第7期1123-1130,共8页世界胃肠病学杂志（英文版）

摘　　要：The risk of liver injury in patients with coronavirus disease 2019(COVID-19)infection is quite evident.Furthermore,liver function test abnormalities are still detected in COVID-19 patients despite the development of antivirals and the availability of several types of vaccines.This editorial describes liver involvement during COVID-19 infection in patients with or without preexisting liver injury,such as chronic liver disease,to elucidate COVID-19-induced liver function abnormalities and their severity,pathophysiology,clinical manifestations,and clinical and laboratory outcomes.We also discuss the effect of vaccination against COVID-19 to better understand host factors,such as age,gender,and race,on the incidence and severity of liver dysfunction at initial presentation and during the illness.Finally,we summarize the results of relevant meta-analyses published to date and highlight the importance of adequate liver function monitoring in the current climate of the overwhelming COVID-19 pandemic.

关 键 词：COVID-19 SARS-CoV-2 Liver injury TRANSAMINASES HYPERBILIRUBINEMIA PATHOPHYSIOLOGY 

分 类 号：R563.1[医药卫生—呼吸系统] R575[医药卫生—内科学]